Influenza Vaccination in Patients Living With HIV in the Northern Region

HIV Clinical Trial

— VACCIGRIPPE  

Official title:

Influenza Vaccination in Patients Living With HIV in the Northern Region: An Observational Monocentre Study of Blankets, Modalities, Drivers and Brakes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04402684
• Other study ID #: RIPH_2020_5
• Status: Completed
• Start date: April 10, 2020
• Est. completion date: December 30, 2020

Study information

• Verified date: January 2021
• Source: Tourcoing Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Anyone living with the Human Immunodeficiency Virus (HIV) has an indication for annual influenza vaccination. (Vaccination schedule and vaccination recommendations 2019). Influenza is a viral infection that has a significant impact on the health care system. However, vaccination coverage in France is still insufficient with regard to the objectives set at 75% by the WHO and the European Commission. For the 2019-2020 seasonal influenza vaccination campaign, flu vaccination by volunteer pharmacists has become possible throughout the country. Studies that have estimated vaccination coverage among HIV-positive populations are rare and show very low rates.

Description:

Cross-sectional study via a self-questionnaire given to all HIV-infected patients coming for a scheduled consultation as part of their HIV follow-up in the spring of 2020. Non-opposition letter given to the patient. Collection of data a posteriori from the medical file recorded in the eNadis patient file.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 124
• Est. completion date: December 30, 2020
• Est. primary completion date: September 30, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Any adult person living with HIV presenting for a follow-up consultation in the spring of 2020

• People who do not read French may participate if they wish with the help of a medical or paramedical staff member.

• Patient did not object

Exclusion Criteria:

• Minor patients

• Major under guardianship, curatorship, protected person

Related Conditions & MeSH terms

• HIV

Locations

Country	Name	City	State
France	CH Tourcoing	Tourcoing

Sponsors (1)

Lead Sponsor	Collaborator
Tourcoing Hospital

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	questionnaire influenza vaccine coverage	The objective of this questionnaire is to estimate the influenza vaccine coverage among PVVIH followed at the Tourcoing Hospital Center.	through study completion, an average of 1 year
Secondary	modalities of influenza vaccination	To identify the modalities of influenza vaccination when it is carried out	through study completion, an average of 1 year
Secondary	the drivers and disincentives to influenza vaccination	Estimate from patient reports the drivers and disincentives to influenza vaccination in a specific risk population.	through study completion, an average of 1 year